Guidelines for Diagnosis and Management of Ventricular Septal Defect

Diagnostic Evaluation

Three core parameters guide VSD management: defect size expressed as Qp:Qs ratio, presence of left‑ventricular volume overload, and pulmonary‑artery pressure relative to systemic pressure. 1
Physical examination should look for signs of LV volume overload (e.g., displaced apical impulse), increased precordial activity, congestive‑heart‑failure manifestations, and differential upper‑ vs. lower‑extremity blood pressures. 2
Electrocardiography is used to identify QRS axis deviation, atrial enlargement, right‑ or left‑ventricular hypertrophy, and first‑degree AV block. 2
Transthoracic echocardiography is the primary imaging tool; it must delineate defect number, anatomic location (perimembranous, supracristal/outlet, inlet, muscular), size, chamber dimensions, LV function, aortic‑valve prolapse/regurgitation, RV systolic pressure from the tricuspid‑regurgitation jet, and any outflow‑tract obstruction. 3
Cardiac MRI or CT is recommended when echocardiographic windows are suboptimal or to confirm anatomy of atypical VSDs (e.g., inlet or apical muscular defects). 4
Cardiac catheterization is indicated for operability assessment in patients with VSD and pulmonary hypertension or when non‑invasive data are inconclusive; it should be performed at an adult congenital heart‑disease (ACHD) regional center. 4

Class I (mandatory) closure is required when the shunt is hemodynamically significant (Qp:Qs ≥ 1.5:1) and there is LV volume overload with pulmonary‑artery systolic pressure < 50 % of systemic pressure and pulmonary‑vascular resistance < 1/3 of systemic resistance. 1
History of infective endocarditis attributable to the VSD is a Class I indication for closure. 1
Progressive aortic regurgitation caused by aortic‑valve prolapse in perimembranous or supracristal VSDs mandates closure (Class I). 1
Class IIa (reasonable) surgical closure is advised for perimembranous or supracristal VSDs when worsening aortic regurgitation is present. 1
Class IIb (may consider) closure is appropriate when Qp:Qs ≥ 1.5:1 and pulmonary‑artery systolic pressure is 50–67 % of systemic and/or pulmonary‑vascular resistance is 1/3–2/3 of systemic resistance. 1
Class IIb (may consider) closure is also reasonable in adults with a prior episode of VSD‑related infective endocarditis, provided no other contraindications exist. 1

Class III (do not close) when pulmonary‑artery systolic pressure exceeds 2/3 of systemic pressure, pulmonary‑vascular resistance exceeds 2/3 of systemic resistance, or a net right‑to‑left shunt (Eisenmenger physiology) is present. 1

ACE inhibitors are indicated for symptomatic heart failure or significant atrioventricular‑valve regurgitation associated with VSD. 5

Spontaneous closure is common in muscular VSDs (especially apical and mid‑muscular) and in many moderate perimembranous defects, often via aneurysmal tissue formation from the tricuspid valve. 3
Small VSDs can be misinterpreted as innocent murmurs; any systolic murmur accompanied by a thrill should prompt echocardiography. (No citation – omitted)
Loud murmurs from small VSDs may mask the development of double‑chambered right ventricle or subaortic stenosis despite little change in murmur character. 4
High‑velocity tricuspid‑regurgitation jets from right‑ventricular outflow obstruction can be mistaken for pulmonary hypertension; careful assessment of the RV outflow tract is essential. 4

The American Heart Association recommends that a typical VSD presents with a holosystolic murmur at the third to fourth intercostal space, often with a palpable thrill, and patients with severe pulmonary arterial hypertension may present with a single loud second heart sound, cyanosis, and clubbing rather than a prominent murmur 6
The American College of Cardiology suggests looking specifically for signs of left ventricular volume overload: displaced apical impulse, increased precordial activity, and evidence of congestive heart failure 7

The American Heart Association recommends that transthoracic echocardiography is the mainstay of diagnosis and should be obtained in all patients with suspected VSD to assess number, location, and size of defects, chamber sizes and left ventricular function, presence of aortic valve prolapse and degree of aortic regurgitation, and right ventricular systolic pressure estimation from tricuspid regurgitation jet 8, 7
The American College of Cardiology suggests that cardiac MRI should be considered when echocardiographic windows are poor or for complex anatomy 8

The American Heart Association recommends closure when Qp/Qs ≥2.0 with clinical evidence of LV volume overload, history of infective endocarditis, or VSD-associated aortic valve prolapse causing progressive aortic regurgitation 8, 6
The American College of Cardiology suggests that it is reasonable to consider closure when Qp/Qs >1.5 with pulmonary artery pressure <2/3 systemic AND pulmonary vascular resistance <2/3 systemic, or Qp/Qs >1.5 with LV systolic or diastolic dysfunction 8, 6

The American College of Cardiology recommends ACE inhibitors for symptomatic heart failure or significant AV valve regurgitation, diuretics for volume management in symptomatic patients, and beta-blockers may be considered if dynamic obstruction contributes 6, 9

The American Heart Association suggests monitoring for double-chambered right ventricle, discrete subaortic stenosis, and infective endocarditis, as the risk increases 6-fold compared to the general population 6, 9, 10

The American College of Cardiology recommends annual echocardiography to monitor for aortic regurgitation, development of outflow obstruction, and changes in shunt magnitude for unoperated small VSDs, and annual follow-up at specialized adult congenital heart disease centers for patients with residual shunts, pulmonary hypertension, aortic regurgitation, LV dysfunction, or outflow tract obstruction 8, 6

The American Heart Association suggests that catheterization should be performed at an ACHD regional center when assessing operability in patients with VSD and pulmonary arterial hypertension, or when noninvasive data are inconclusive or discrepant with clinical findings 8